IL287213A - Methods for treating patients with psoriatic arthritis - Google Patents
Methods for treating patients with psoriatic arthritisInfo
- Publication number
- IL287213A IL287213A IL287213A IL28721321A IL287213A IL 287213 A IL287213 A IL 287213A IL 287213 A IL287213 A IL 287213A IL 28721321 A IL28721321 A IL 28721321A IL 287213 A IL287213 A IL 287213A
- Authority
- IL
- Israel
- Prior art keywords
- subjects
- treatment
- methods
- psoriatic arthritis
- psoriatic
- Prior art date
Links
- 201000001263 Psoriatic Arthritis Diseases 0.000 title 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921015050 | 2019-04-15 | ||
| IN202021004422 | 2020-01-31 | ||
| PCT/IB2020/053565 WO2020212874A1 (en) | 2019-04-15 | 2020-04-15 | Methods for treatment of subjects with psoriatic arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL287213A true IL287213A (en) | 2021-12-01 |
Family
ID=72837755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL287213A IL287213A (en) | 2019-04-15 | 2021-10-12 | Methods for treating patients with psoriatic arthritis |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220298233A1 (enExample) |
| EP (1) | EP3956357A4 (enExample) |
| JP (2) | JP7628962B2 (enExample) |
| KR (1) | KR20210140780A (enExample) |
| CN (1) | CN113825768A (enExample) |
| AU (1) | AU2020259375A1 (enExample) |
| BR (1) | BR112021020612A2 (enExample) |
| CA (1) | CA3143604A1 (enExample) |
| IL (1) | IL287213A (enExample) |
| JO (1) | JOP20210279A1 (enExample) |
| MA (1) | MA55729A (enExample) |
| MX (1) | MX2021012652A (enExample) |
| MY (1) | MY210310A (enExample) |
| PH (1) | PH12021552536A1 (enExample) |
| SG (1) | SG11202111056YA (enExample) |
| WO (1) | WO2020212874A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025036280A1 (zh) * | 2023-08-11 | 2025-02-20 | 信达生物制药(苏州)有限公司 | 既往接受生物制剂治疗斑块状银屑病的受试者转用抗IL23p19抗体治疗斑块状银屑病的方法 |
| TW202511290A (zh) * | 2023-09-07 | 2025-03-16 | 大陸商信達生物製藥（蘇州）有限公司 | 一種重組抗ＩＬ－２３ｐ１９抗體治療中重度銀屑病的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7807389B2 (en) * | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
| EP2666472A3 (en) * | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Uses and compositions for treatment of psoriatic arthritis |
| US8293883B2 (en) * | 2007-02-23 | 2012-10-23 | Schering Corporation | Engineered anti-IL-23P19 antibodies |
| AU2009288419B2 (en) * | 2008-08-27 | 2015-08-06 | Merck Sharp & Dohme Llc | Lyophilized formulatons of engineered anti-IL-23p19 antibodies |
| JP6126532B2 (ja) * | 2010-11-04 | 2017-05-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ｉｌ−２３抗体 |
| WO2014004436A2 (en) | 2012-06-27 | 2014-01-03 | Merck Sharp & Dohme Corp. | Crystalline anti-human il-23 antibodies |
-
2020
- 2020-04-15 CA CA3143604A patent/CA3143604A1/en active Pending
- 2020-04-15 KR KR1020217037137A patent/KR20210140780A/ko active Pending
- 2020-04-15 MX MX2021012652A patent/MX2021012652A/es unknown
- 2020-04-15 CN CN202080029205.6A patent/CN113825768A/zh active Pending
- 2020-04-15 AU AU2020259375A patent/AU2020259375A1/en active Pending
- 2020-04-15 BR BR112021020612A patent/BR112021020612A2/pt unknown
- 2020-04-15 PH PH1/2021/552536A patent/PH12021552536A1/en unknown
- 2020-04-15 JP JP2021561000A patent/JP7628962B2/ja active Active
- 2020-04-15 MA MA055729A patent/MA55729A/fr unknown
- 2020-04-15 WO PCT/IB2020/053565 patent/WO2020212874A1/en not_active Ceased
- 2020-04-15 JO JOP/2021/0279A patent/JOP20210279A1/ar unknown
- 2020-04-15 SG SG11202111056YA patent/SG11202111056YA/en unknown
- 2020-04-15 US US17/603,921 patent/US20220298233A1/en active Pending
- 2020-04-15 MY MYPI2021005910A patent/MY210310A/en unknown
- 2020-04-15 EP EP20790874.0A patent/EP3956357A4/en active Pending
-
2021
- 2021-10-12 IL IL287213A patent/IL287213A/en unknown
-
2025
- 2025-01-30 JP JP2025013906A patent/JP2025069284A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3956357A1 (en) | 2022-02-23 |
| JP2025069284A (ja) | 2025-04-30 |
| PH12021552536A1 (en) | 2022-07-04 |
| CA3143604A1 (en) | 2020-10-22 |
| CN113825768A (zh) | 2021-12-21 |
| KR20210140780A (ko) | 2021-11-23 |
| EP3956357A4 (en) | 2023-01-04 |
| JP7628962B2 (ja) | 2025-02-12 |
| SG11202111056YA (en) | 2021-11-29 |
| MY210310A (en) | 2025-09-10 |
| AU2020259375A1 (en) | 2021-10-28 |
| MX2021012652A (es) | 2022-01-24 |
| JP2022529266A (ja) | 2022-06-20 |
| MA55729A (fr) | 2022-02-23 |
| WO2020212874A1 (en) | 2020-10-22 |
| BR112021020612A2 (pt) | 2021-12-28 |
| US20220298233A1 (en) | 2022-09-22 |
| JOP20210279A1 (ar) | 2023-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202100528B (en) | Acid gas treatment | |
| IL291735A (en) | Heteroarylbiphenylamines for the treatment of pd-l1 diseases | |
| IL286653A (en) | Methods for treating muscular dystrophy with Casimersen | |
| SG11202104222TA (en) | Method of treatment of biological surfaces | |
| IL286000A (en) | Asketamine for the treatment of depression | |
| IL259486A (en) | Substances for the treatment of diseases associated with unwanted cell proliferation | |
| IL284791A (en) | Disease treatment methods with MAGL inhibitors | |
| IL287213A (en) | Methods for treating patients with psoriatic arthritis | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| GB201808575D0 (en) | Methods for the treatment of psoriatic arthrits | |
| GB202015959D0 (en) | Treatment of diseases involving NAD | |
| IL290770A (en) | Compounds and methods for treating oxalate-related diseases | |
| PL3431656T3 (pl) | Sposób obróbki kamieni tłuczniowych | |
| IL281480B (en) | Process and device for treating organic matter | |
| GB201918853D0 (en) | Methods of treatment | |
| SG11202105877YA (en) | Method of treatment | |
| HUP1800109A2 (en) | Process and equipment for the treatment of biomass | |
| IL286099A (en) | Methods of treating the disease using levoketoconazole | |
| IL290983A (en) | Treatment methods | |
| HK40067726A (en) | Methods for treatment of subjects with psoriatic arthritis | |
| PL3292226T3 (pl) | Sposób obróbki szlamu zawierającego żelazo | |
| EP4027805C0 (en) | CONTINUOUSLY OPERATING AUTOCLAVE | |
| IL269681A (en) | New methods for treating multiple sclerosis | |
| ZA202001642B (en) | Method for the treatment of iron-containing sludge | |
| GB201902634D0 (en) | Apparatus for the treatment of malaria |